Trial reportBMJ open2023
Multicentre, randomised, double-blind, parallel controlled trial to investigate timing of platelet inhibition after coronary artery bypass grafting: TOP-CABG trial study.
Trial report in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05380063 (Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in Patients Without Acute Coronary Syndrome), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in Patients Without Acute Coronary Syndrome
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial.BMJ (Clinical research ed.) · 2026Trial
- Extent of coronary artery disease and clinical outcomes with ticagrelor monotherapy versus aspirin after coronary artery bypass grafting: insights from the TiCAB trial.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025Trial
- Patient-centred anti-platelet therapy following coronary artery bypass graft surgery.Journal of thrombosis and thrombolysis · 2026Review
- Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs.Journal of clinical medicine · 2026Review
- Aspirin Responsiveness and Early Saphenous Vein Graft Occlusion After Coronary Artery Bypass Grafting: A CT Coronary Angiography Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Acute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention.Journal of clinical medicine · 2025Review
- Saphenous vein graft and nitric oxide: strategies to prevent graft failure and enhance patency in coronary artery bypass grafting.Frontiers in cardiovascular medicine · 2025Review
- The impact of clopidogrel combined with aspirin or aspirin alone on prognosis and adverse events in patients undergoing coronary artery bypass grafting in the first month after surgery.Frontiers in cardiovascular medicine · 2025Article
- Antithrombotic strategies for preventing graft failure in coronary artery bypass graft.Journal of thrombosis and thrombolysis · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDual antiplatelet therapy (DAPT), referred to as the combination of aspirin and P2Y METHODS AND ANALYSIS: ETHICS AND DISSEMINATION: The Ethics Committee in Fuwai hospital approved this study (2022-1774). Fifteen centres agreed to participate the TOP-CABG trial, and the study has been approved in these 15 centres by whose ethics committee. The results of the trial will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT05380063.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.